Skip to main content
European Commission logo
English English
CORDIS - EU research results

Article Category

Content archived on 2024-03-25

Article available in the following languages:


AMYPAD Prognostic and Natural History Study reaches milestone of 1.000 research participants

The members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) initiative reached a significant milestone this month with the enrolment of the 1.000th research participant in its Prognostic and Natural History Study (PNHS).

Fundamental Research icon Fundamental Research

In this clinical study, researchers aim at understanding the role of amyloid imaging in the earliest stages of Alzheimer’s disease to increase the chances of successful secondary prevention trials. The study recruits individuals suspected of possible Alzheimer’s disease from various ongoing European parent cohorts. Recruitment started in late 2018 and is expected to continue until March 2022. By the end of May 2021, 1.471 participants have been informed about the study, 1.001 consented, and 835 already underwent their amyloid PET scan. We are pleased that 42 new research participants were enrolled in the study in May. It continues the positive trend in recruitment of research participants as there was 51 participants that consented in March and 47 participants that consented in April. At this moment, the PNHS has 17 active sites and 7 cohorts have been actively enrolling into the study (EPAD LCS, EMIF-AD, ALFA+, FACEHBI, FPACK, UCL-2020-412, Microbiota), with two other confirmed to begin enrolment soon. It has also been very rewarding, since a new cohort (Microbiota) has joined the AMYPAD PNHS study and started recruitment. Finally, the data integration process (from all data sources) and quality check of data has been initiated and the team has also conducted the first exploratory analyses of PNHS data. This study was designed to evaluate the additional value of quantitative amyloid imaging in determining Alzheimer’s disease dementia risk based on quantitative PET amyloid imaging measures, with or without other biomarkers. “I think it is amazing that my visit to AMYPAD is contributing to the important research goals of AMYPAD. Contributing to such a large study with all these cohorts makes me feel like my effort will have true effect and this make me very happy!”, said Dhr. V. – a research participant of the AMYPAD prognostic study. “The study is conducted very carefully and I am glad to have the opportunity to be part of it and contribute to Alzheimer’s research!”, said another research participant. The AMYPAD Europe-wide initiative aims to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of β-amyloid PET imaging. The 5-year large-scale study involves 15 organisations including academic and industrial partners, SMEs and patient organisations, and it is funded by the IMI-2 program. For further information, visit or please contact:


alzheimer, prevention, amyloid